Literature DB >> 10815903

Association of allelic loss on 1q, 4p, 7q, 9p, 9q, and 16q with postoperative death in papillary thyroid carcinoma.

Y Kitamura1, K Shimizu, S Tanaka, K Ito, M Emi.   

Abstract

Papillary thyroid carcinomas, most of which are characterized by slow growth and good prognosis, account for the majority of thyroid carcinomas. To provide appropriate postoperative management, it is important to classify them by prediction of their prognosis. To find genetic markers associated with poor prognosis, allelic loss at all 39 nonacrocentric chromosome arms was compared in 24 deceased cases and 45 age-, sex-, stage-, and type-matched survived cases. Allelic loss was examined in primary tumors from both groups using highly polymorphic microsatellite markers on 39 nonacrocentric autosomal arms. Age at diagnosis, sex, stage, and types of tumors were matched between the two groups. No recurrent tumor was used for DNA analysis. Mean fractional allelic loss in the deceased and survived cases was 0.10+/-0.08 and 0.03+/-0.05 (P < 0.001). The survived cases showed marginal frequencies of allelic loss throughout all chromosome arms except 22q. The deceased cases showed frequent allelic losses on chromosomes 1q (37%), 4p (21%), 7q (20%), 9p (36%), 9q (31%), and 16q (29%), with significant difference (P < 0.05). These chromosome regions may include tumor suppressor genes whose inactivation is associated with aggressive phenotypes of papillary thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10815903

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

1.  Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas.

Authors:  Liliána Z Fehér; Gábor Pocsay; László Krenács; Agnes Zvara; Enikő Bagdi; Réka Pocsay; Géza Lukács; Ferenc Győry; Andrea Gazdag; Erzsébet Tarkó; László G Puskás
Journal:  Pathol Oncol Res       Date:  2011-12-11       Impact factor: 3.201

2.  Tumor heterogeneity in a follicular carcinoma of thyroid: a study by comparative genomic hybridization.

Authors:  Leonard Da Silva; Daniel James; Peter T Simpson; Daniel Walker; Ana Cristina Vargas; Janani Jayanthan; Sunil R Lakhani; Anne Marie McNicol
Journal:  Endocr Pathol       Date:  2011-06       Impact factor: 3.943

3.  A family with spinal anaplastic ependymoma: evidence of loss of chromosome 22q in tumor.

Authors:  Takashi Yokota; Takayuki Tachizawa; Koichi Fukino; Akira Teramoto; Jun Kouno; Koshi Matsumoto; Mitsuru Emi
Journal:  J Hum Genet       Date:  2003-10-18       Impact factor: 3.172

Review 4.  Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies?

Authors:  Esther Korpershoek; Karel Pacak; Lucia Martiniova
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

5.  Decreased expression of haemoglobin beta (HBB) gene in anaplastic thyroid cancer and recovery of its expression inhibits cell growth.

Authors:  M Onda; J Akaishi; S Asaka; J Okamoto; S Miyamoto; K Mizutani; A Yoshida; K Ito; M Emi
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

6.  The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression.

Authors:  A Ferru; G Fromont; H Gibelin; J Guilhot; F Savagner; J M Tourani; J L Kraimps; C J Larsen; L Karayan-Tapon
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640

7.  Clinicopathological Significance of Overall Frequency of Allelic Loss (OFAL) in Lesions Derived from Thyroid Follicular Cell.

Authors:  Monika Migdalska-Sęk; Karolina H Czarnecka; Michał Kusiński; Dorota Pastuszak-Lewandoska; Ewa Nawrot; Krzysztof Kuzdak; Ewa Brzeziańska-Lasota
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

8.  Loss of Heterozygosities in Five Tumor Suppressor Genes (FHIT Gene, p16, pRb, E-Cadherin and p53) in Thyroid Tumors.

Authors:  Jin Hwan Kim; Kyu Young Choi; Dong Jin Lee; Young-Soo Rho; Sung-Jin Jo
Journal:  Clin Exp Otorhinolaryngol       Date:  2014-02-05       Impact factor: 3.372

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.